Lesley Liu‐Bujalski

Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

Andrew T. Bender, A.S. Gardberg, Albertina Pereira et al. · Molecular Pharmacology · 2017 · 188 citations

Life Sciences, Immunology, Pharmacology +17

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models

Philipp Haselmayer, Montserrat Camps, Lesley Liu‐Bujalski et al. · The Journal of Immunology · 2019 · 148 citations · Full text

Medicine, Immunology, Pharmacology +17

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 140 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Btk inhibition treats TLR7/IFN driven murine lupus

Andrew T. Bender, Albertina Pereira, Kai Fu et al. · Clinical Immunology · 2016 · 54 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit

Hui Qiu, Lesley Liu‐Bujalski, Richard D. Caldwell et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 24 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14